How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

591 results for

Malaria Chemoprophylaxis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Chemoprophylaxis of Homozygous Sicklers with Antimalarials and Long-acting Penicillin Full Text available with Trip Pro

Chemoprophylaxis of Homozygous Sicklers with Antimalarials and Long-acting Penicillin 14305376 1996 12 01 2018 12 01 0007-1447 2 5453 1965 Jul 10 British medical journal Br Med J CHEMOPROPHYLAXIS OF HOMOZYGOUS SICKLERS WITH ANTIMALARIALS AND LONG-ACTING PENICILLIN. 86-8 WARLEY M A MA HAMILTON P J PJ MARSDEN P D PD BROWN R E RE MERSELIS J G JG WILKS N N eng Journal Article England Br Med J 0372673 0007-1447 0 Antimalarials 0 Delayed-Action Preparations 0 Ethylenediamines 0 Placebos 886U3H6UFF (...) Chloroquine C659VZ7P7T benzathine Q42T66VG0C Penicillin G RIT82F58GK Penicillin G Benzathine OM Adolescent Anemia Anemia, Sickle Cell Antimalarials Biomedical Research Chemoprevention Child Chloroquine Delayed-Action Preparations Drug Therapy Ethylenediamines Fingers Humans Infant Inflammation Malaria Penicillin G Penicillin G Benzathine Placebos Preventive Medicine Respiratory Tract Infections Statistics as Topic Toes Uganda ADOLESCENCE ANEMIA, SICKLE CELL CHILD CHLOROQUINE CLINICAL RESEARCH DELAYED

1965 British medical journal

142. Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults

21 days (3 weeks) after the booster dose (Booster Phase Study Day 21). Outcome Measures Go to Primary Outcome Measures : Number of Subjects With Plasmodium Falciparum Parasitemia Defined by a Positive Blood Slide, Following Sporozoite Challenge [ Time Frame: 28 days post-challenge (Study Day 245) ] The definition of malaria for primary and secondary efficacy outcomes is the appearance of asexual blood stage P. falciparum parasites detected by blood slide at any time post challenge/rechallenge up (...) With Plasmodium Falciparum Parasitemia Defined by a Positive Blood Slide, Following Sporozoite Rechallenge [ Time Frame: Up to 28 days post rechallenge (Booster Phase Day 49) ] The definition of malaria infection for primary and secondary efficacy outcomes is the appearance of asexual blood stage P. falciparum parasites detected by blood slide at any time post challenge/rechallenge up to 28 days. Time to Onset of P. Falciparum Parasitemia Infection Defined by a Positive Blood Slide, Following Sporozoite

2013 Clinical Trials

143. Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial. Full Text available with Trip Pro

Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial. Immunization of volunteers under chloroquine prophylaxis by bites of Plasmodium falciparum sporozoite (PfSPZ)-infected mosquitoes induces > 90% protection against controlled human malaria infection (CHMI). We studied intradermal immunization with cryopreserved, infectious (...) PfSPZ in volunteers taking chloroquine (PfSPZ chemoprophylaxis vaccine [CVac]). Vaccine groups 1 and 3 received 3× monthly immunizations with 7.5 × 10(4) PfSPZ. Control groups 2 and 4 received normal saline. Groups 1 and 2 underwent CHMI (#1) by mosquito bite 60 days after the third immunization. Groups 3 and 4 were boosted 168 days after the third immunization and underwent CHMI (#2) 137 days later. Vaccinees (11/20, 55%) and controls (6/10, 60%) had the same percentage of mild to moderate

2015 The American journal of tropical medicine and hygiene Controlled trial quality: uncertain

144. Absence of association between Plasmodium falciparum small sub-unit ribosomal RNA gene mutations and in vitro decreased susceptibility to doxycycline. Full Text available with Trip Pro

Absence of association between Plasmodium falciparum small sub-unit ribosomal RNA gene mutations and in vitro decreased susceptibility to doxycycline. Doxycycline is an antibiotic used in combination with quinine or artesunate for malaria treatment or alone for malaria chemoprophylaxis. Recently, one prophylactic failure has been reported, and several studies have highlighted in vitro doxycycline decreased susceptibility in Plasmodium falciparum isolates from different areas. The genetic

2015 Malaria journal

145. Imported malaria including HIV and pregnant woman risk groups: overview of the case of a Spanish city 2004-2014. Full Text available with Trip Pro

Imported malaria including HIV and pregnant woman risk groups: overview of the case of a Spanish city 2004-2014. Arrival of inmigrants from malaria endemic areas has led to a emergence of cases of this parasitic disease in Spain. The objective of this study was to analyse the high incidence rate of imported malaria in Fuenlabrada, a city in the south of Madrid, together with the frequent the lack of chemoprophylaxis, for the period between 2004 and 2014. Both pregnant women and HIV risk groups (...) have been considered.Retrospective descriptive study of laboratory-confirmed malaria at the Fuenlabrada University Hospital, in Madrid, during a 10-year period (2004-2014). These data were obtained reviewing medical histories of the cases. Relevant epidemiological, clinical and laboratory results were analysed, with focus on the following risk groups: pregnant women and individuals with HIV.A total of 185 cases were diagnosed (90.3 % Plasmodium falciparum). The annual incidence rate was 11.9

2015 Malaria journal

146. Cluster of Imported Vivax Malaria in Travelers Returning From Peru. Full Text available with Trip Pro

Cluster of Imported Vivax Malaria in Travelers Returning From Peru. We report a cluster of imported vivax malaria in three of five Chilean travelers returning from Peru in March 2015. The cluster highlights the high risk of malaria in the Loreto region in northern Peru, which includes popular destinations for international nature and adventure tourism. According to local surveillance data, Plasmodium vivax is predominating, but Plasmodium falciparum is also present, and the incidence of both (...) species has increased during recent years. Travelers visiting this region should be counseled about the prevention of malaria and the options for chemoprophylaxis. © 2015 International Society of Travel Medicine.

2015 Journal of Travel Medicine

147. Evaluation of single nucleotide polymorphisms of pvmdr1 and microsatellite genotype in Plasmodium vivax isolates from Republic of Korea military personnel. Full Text available with Trip Pro

Evaluation of single nucleotide polymorphisms of pvmdr1 and microsatellite genotype in Plasmodium vivax isolates from Republic of Korea military personnel. Chloroquine has been administered to the soldiers of the Republic of Korea as prophylaxis against vivax malaria. Recent increase in the number of chloroquine-resistant parasites has raised concern over the chemoprophylaxis and treatment of vivax malaria.To monitor the development of chloroquine-resistant parasites in the Republic of Korea (...) , analyses of single nucleotide polymorphisms (SNPs) of pvmdr1 and microsatellite markers were performed using samples collected from 55 South Korean soldiers infected with Plasmodium vivax.Four SNPs, F1076L, T529, E1233, and S1358, were identified. Among these, S1358 was detected for the first time in Korea. The microsatellite-based study revealed higher genetic diversity in samples collected in 2012 than in 2011.Taken together, the results indicate that P. vivax with a newly identified SNP of pvmdr1

2015 Malaria journal

148. Ex vivo lymphocyte phenotyping during Plasmodium falciparum sporozoite immunization in humans. Full Text available with Trip Pro

Ex vivo lymphocyte phenotyping during Plasmodium falciparum sporozoite immunization in humans. Immunization of malaria-naïve volunteers under chemoprophylaxis with Plasmodium falciparum sporozoites (CPS) efficiently and reproducibly induces sterile protection and thus constitutes an excellent model to study protective immune responses against malaria. Here, we performed the first longitudinal assessment of lymphocyte activation and differentiation kinetics during sporozoite immunization in 15

2015 Parasite immunology

149. Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force Full Text available with Trip Pro

Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force The Australian Defence Force (ADF) has used mefloquine for malaria chemoprophylaxis since 1990. Mefloquine has been found to be a plausible cause of a chronic central nervous system toxicity syndrome and a confounding factor in the diagnosis of existing neuropsychiatric illnesses prevalent in the ADF such as posttraumatic stress disorder and traumatic brain injury

2015 Journal of parasitology research

150. Recommendations for malaria prevention in moderate to low risk areas: travellers' choice and risk perception. Full Text available with Trip Pro

of malaria, anti-malarial adverse drug reactions and other travel-related risks, inspired by Paling palettes from the Risk Communication Institute.A total of 391 travellers were included from December 2012 to December 2013. Fifty-nine (15%) opted for chemoprophylaxis, 116 (30%) for stand-by emergency treatment, 112 (29%) for stand-by emergency treatment with rapid diagnostic test, 100 (26%) for bite prevention only, and four (1%) for other choices. Travellers choosing chemoprophylaxis justified (...) Recommendations for malaria prevention in moderate to low risk areas: travellers' choice and risk perception. The considerable malaria decline in several countries challenges the strategy of chemoprophylaxis for travellers visiting moderate- to low-risk areas. An international consensus on the best strategy is lacking. It is essential to include travellers' opinions in the decision process. The preference of travellers regarding malaria prevention for moderate- to low-risk areas, related

2015 Malaria journal

151. Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases. Full Text available with Trip Pro

-endemic areas and presented a parasitaemia > 5% of erythrocytes and clinical signs of severe falciparum malaria, both with > 350 CD4 cell count/μl, absence of chemoprophylaxis and successful response. Factors like drug interactions and the possible implication of anti-malarial therapy bioavailability are all especially interesting in HIV-malaria co-infections. (...) Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases. As HIV becomes a chronic infection, an increasing number of HIV-infected patients are travelling to malaria-endemic areas. Association of malaria with HIV/AIDS can be clinically severe. Severe falciparum malaria is a medical emergency that is associated with a high mortality, even when treated in an Intensive Care Unit. This article describes two cases of HIV-positive patients, who returned from malaria

2012 Malaria journal

152. Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

of malaria ever, or use of malaria chemoprophylaxis within 60 days prior to vaccination Known exposure to malaria within the past 12 months or planned travel to malarious area during the study period Confirmed or suspected immunosuppressive or immunodeficient condition Family history of congenital or hereditary immunodeficiency History of allergic disease or reactions likely to be exacerbated by any component of the vaccine Chronic or active neurologic disease including seizures History of splenectomy (...) Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x

2012 Clinical Trials

153. Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

or disease Intervention/treatment Phase Malaria Plasmodium Falciparum Biological: PfSPZ Challenge Biological: Normal Saline (NS) Phase 1 Detailed Description: The study is a single centre, double blind, randomized controlled clinical trial. Volunteers, investigators and laboratory personnel will be blinded. A maximum of 30 volunteers will be randomly divided into four groups. All volunteers will receive standard weekly chloroquine chemoprophylaxis for a period of 14 weeks (98 days). During this period (...) : November 20, 2012 Last Update Posted: May 15, 2017 Last Verified: May 2014 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by Sanaria Inc.: Malaria Plasmodium falciparum PfSPZ Challenge Chemoprophylaxis PfSPZ-CVac Additional relevant MeSH terms: Layout table for MeSH terms Malaria Protozoan Infections Parasitic Diseases Vaccines Chloroquine Chloroquine diphosphate Immunologic Factors Physiological

2012 Clinical Trials

154. Limited evidence on most effective prophylaxis for chloroquine-resistant malaria

Limited evidence on most effective prophylaxis for chloroquine-resistant malaria PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Limited evidence on most effective prophylaxis for chloroquine-resistant malaria Clinical question What is the most effective and safest prophylactic anti- malarial for non-immune adults and children travelling to regions with Plasmodium falciparum resistance (...) travellers each year. It can be prevented through anti-mosquito measures and drug prophylaxis. However, anti-malarial drugs have adverse effects which are sometimes serious. Cochrane Systematic Review Jacquerioz FA and Croft AM. Drugs for preventing malaria in travellers. Cochrane Reviews 2009, Issue 4. Article No. CD006491. DOI: 10.1002/14651858.CD006491.pub2. This review contains 8 studies involving 4240 participants. are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether

2011 Cochrane PEARLS

155. Review: malaria chemoprophylaxis for travelers to latin america. Full Text available with Trip Pro

Review: malaria chemoprophylaxis for travelers to latin america. Because of recent declining malaria transmission in Latin America, some authorities have recommended against chemoprophylaxis for most travelers to this region. However, the predominant parasite species in Latin America, Plasmodium vivax, can form hypnozoites sequestered in the liver, causing malaria relapses. Additionally, new evidence shows the potential severity of vivax infections, warranting continued consideration (...) of prophylaxis for travel to Latin America. Individualized travel risk assessments are recommended and should consider travel locations, type, length, and season, as well as probability of itinerary changes. Travel recommendations might include no precautions, mosquito avoidance only, or mosquito avoidance and chemoprophylaxis. There are a range of good options for chemoprophylaxis in Latin America, including atovaquone-proguanil, doxycycline, mefloquine, and--in selected areas--chloroquine. Primaquine

2011 American Journal of Tropical Medicine & Hygiene

156. Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries. Full Text available with Trip Pro

transmission risk using imported malaria cases and numbers of travellers to malarious countries. By calculating the minimal threshold malaria risk below which the economic costs of chemoprophylaxis are greater than the avoided health costs we were able to identify the point at which chemoprophylaxis would be economically rational.The threshold incidence at which malaria chemoprophylaxis policy becomes cost effective for UK travellers is an accumulated risk of 1.13% assuming a given set of cost parameters (...) Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries. In a number of malaria endemic regions, tourists and travellers face a declining risk of travel associated malaria, in part due to successful malaria control. Many millions of visitors to these regions are recommended, via national and international policy, to use chemoprophylaxis which has a well recognized morbidity profile. To evaluate whether current malaria chemo-prophylactic policy

2011 Malaria journal

157. Malaria chemoprophylaxis recommendations for immigrants to Europe, visiting relatives and friends - a Delphi method study. Full Text available with Trip Pro

Malaria chemoprophylaxis recommendations for immigrants to Europe, visiting relatives and friends - a Delphi method study. Numbers of travellers visiting friends and relatives (VFRs) from Europe to malaria endemic countries are increasing and include long-term and second generation immigrants, who represent the major burden of malaria cases imported back into Europe. Most recommendations for malaria chemoprophylaxis lack a solid evidence base, and often fail to address the cultural, social (...) experience of participants was rather diverse as was their selection of chemoprophylaxis regimen. A significant consensus was observed in only seven of 16 scenarios. The analysis revealed a wide variation in prescribing choices with preferences grouped by region of practice and increased prescribing seen in Northern Europe compared to Central Europe.Improving the evidence base on efficacy, adherence to chemoprophylaxis and risk of malaria and encouraging discussion among experts, using techniques

2011 Malaria journal

158. No, sleeping with a chicken probably won’t save you from Zika or malaria

of defense against malaria. “Measures to prevent mosquito bites include sleeping under long-lasting insecticidal nets, and using protective clothing and insect repellents. Depending on the malaria risk in the area to be visited, international travellers may also need to take preventive medication (chemoprophylaxis) prior to, during, and upon return from their travel.” NPR’s story included a comment from an outside source who thought the study was “pretty cool.” But I didn’t see any hint of skepticism (...) No, sleeping with a chicken probably won’t save you from Zika or malaria No, sleeping with a chicken probably won't save you from Zika or malaria - HealthNewsReview.org Note to our followers: Our nearly 13-year run of daily publication of new content on HealthNewsReview.org came to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain lessons to help you improve your critical

2016 HealthNewsReview

159. Review: provider practice and user behavior interventions to improve prompt and effective treatment of malaria: do we know what works?

eligible for inclusion. Providers were defined as dispensers of anti-malarial drugs and users as consumers of anti-malarial drugs. Studies were required to report at least one component of the Roll Back Malaria outcome indicator (i.e. percentage of patients getting correct type, dose and duration of treatment at health facility, and community levels within 24 hours of symptom onset). The intervention could target malaria alone or in combination with other diseases. Randomised controlled trials (RCTs (...) ), pre/post studies, time series, and post-only evaluations with a control group, were eligible. Studies of chemoprophylaxis, mass drug administration, traveller health or severe malaria (only) were excluded. Most of the user populations in the included studies were children aged under five years and (if relevant) their caretakers. The studies targeted diverse groups, most of whom were providers, either in the public (governmental) or the private (for-profit or non-governmental) sector. Providers

2009 DARE.

160. Post-mortem diagnosis of malaria Full Text available with Trip Pro

England New Microbes New Infect 101624750 2052-2975 Chemoprophylaxis malaria real-time PCR sudden death 2014 03 22 2014 04 25 2014 05 12 2014 10 31 6 0 2014 10 31 6 0 2014 10 31 6 1 ppublish 25356366 10.1002/nmi2.52 PMC4184481 Am J Forensic Med Pathol. 2000 Dec;21(4):366-9 11111799 Infection. 2005 Feb;33(1):33-5 15750758 Int J Legal Med. 2000;113(4):251-2 10929245 Leg Med (Tokyo). 2012 May;14(3):111-5 22369777 J Forensic Sci. 2003 Mar;48(2):404-8 12665001 Clin Microbiol Infect. 2011 Mar;17(3):469-75 (...) Post-mortem diagnosis of malaria 25356366 2014 10 30 2018 11 13 2052-2975 2 5 2014 Sep New microbes and new infections New Microbes New Infect Post-mortem diagnosis of malaria. 154-5 10.1002/nmi2.52 Palmiere C C University Centre of Legal Medicine, University Hospital Centre and University of Lausanne Lausanne, Switzerland ; Hospital Centre of Sion Sion, Switzerland. Jaton K K Institute of Microbiology, University Hospital Centre and University of Lausanne Lausanne, Switzerland. Lobrinus

2014 New Microbes and New Infections

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>